Public-private partnership launched to develop new drugs for roundworm infections

Geneva – 28 November 2019 

“Pan-nematode” drug development platform is part of Europe’s Horizon 2020 programme

A new consortium of research institutes, universities, not-for-profit organizations, and pharmaceutical companies has teamed up to develop novel drugs for infections caused by parasitic worms (helminths), a debilitating group of diseases that includes river blindness, lymphatic filariasis, as well as infection with hookworm and whipworm, which together affect close to a billion people.

Read more

Comments are closed.